SENZUMODERN REBIRTHMy account Ipamorelin
Also known as NNC 26-0161 · ipamorelin acetate
A randomized phase 2 postoperative-ileus study found no statistically significant improvement in its key or secondary efficacy endpoints. Early volunteer studies establish pharmacology, not wellness benefit.
- Evidence maturity
- Early signal
- Regulatory status
- Not FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 3
This profile does not recommend a compound, dose, supplier, or treatment plan. Discuss personal decisions with a qualified clinician who knows your history.
Summary
An unapproved ghrelin-receptor agonist and growth-hormone secretagogue with limited clinical development.
What is Ipamorelin being studied for?
Growth hormone and gastrointestinal motility
How is it thought to work?
Activates the ghrelin or growth-hormone-secretagogue receptor, stimulating GH release and gastrointestinal motility pathways.
Recorded outcomes
3 graded outcomes and 3 sources for Ipamorelin.
The graded outcome table, how each grade was decided, the regulatory detail, and every source with its link and identifier open with a free account. No payment details required.
Update history
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.